லுகேமியா ஜர்னல்
திறந்த அணுகல்

சுருக்கம்

Angiogenesis in Leukemias: A Review

Susy Ricardo Lemes*, Luciana Cardoso Marinho, Katia Karina Veroli de Oliveira Moura, Fatima Mrue, Paulo Roberto de Melo-Reis

Objectives: This study aimed to investigate the influence of the angiogenic process on the development of leukemias.

Methods: A systematic review was performed based on 230 published manuscripts, 90 of which between 1995 and 2016, involving in vitro and in vivo experiments and reviews of the angiogenic process, types of leukemias and angiogenic factors involved in the origin of tumors. Searches were carried out in the Latin American and Caribbean Literature in Health Sciences (LILACS), Scientific electronic library online (Scielo), Scopus and Pubmed databases, among others. We excluded articles that did not report the relationship between angiogenesis and leukemias or angiogenic factors and leukemias.

Results: Evidence suggests that angiogenic factors such as FGF, HGF, TGF, TNF, HIF-1, MMPs, the c-Myc gene, endothelin and especially VEGF are strongly expressed in malignant cells and can lead, for example, to hematological malignancy. Regulation of mirRNA expression, such as miR-17 and miR-20a, is also involved in the abnormal proliferation, differentiation and apoptosis of these cells.

Conclusion: Some angiogenic factors such as VEGF, MMPs and FGF act not only on initiation, but also on the progression, metastasis and apoptosis of solid tumor cells and leukemias, which may favor the development of a target-based therapy against angiogenesis in leukemias. As such, angiogenesis inhibitors aim to inhibit tumor growth and metastasis.